Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer

Oncology

Volumn 78, Issue 5-6, 2010, Pages 369-375

  Carlomagno, Chiara ^a   Pepe, Stefano ^a   D'Armiento, Francesco Paolo ^a   D'Armiento, Maria ^a   Cannella, Lucia ^a   De Stefano, Alfonso ^a   Crispo, Anna ^b   Giordano, Marcella ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Epidermal growth factor receptor; Neoadjuvant chemoradiotherapy; Predictive factors; Rectal cancer

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; THYMIDYLATE SYNTHASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; TREATMENT RESPONSE; TUMOR BIOPSY; CANCER STAGING; COLONOSCOPY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTIVE VALUE; RADIOTHERAPY; RECTAL NEOPLASMS; REGRESSION ANALYSIS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; COLONOSCOPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY; RECTAL NEOPLASMS; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 77956074222     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320464     Document Type: Article

References (56)

1. Gerard JP, Conroy T, Bonnetain F, et al: Preoperative radiotherapy, with or without concurrent 5fluorouracil and leucovorin in T3- T4 rectal cancers: results of the FFCD 9203 trial. J Clin Oncol 2006; 24: 4620-4625.
2. Bosset JF, Colette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
3. Braendengen M, Tveit KM, Berglund A, et al: Randomized phase III trial comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3686-3694.
4. Bouzourene H, Bosman FT, Seelentag W, et al: Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002; 94: 1121-1130.
5. Rodel C, Martus P, Papadopulos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
6. Chan AKP, Wong A, Jenken D, et al: Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Rad Oncol Biol Phys 2005; 61: 665-676.
7. Suarez J, Vera R, Balén E, et al: Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 2007; 10: 563-568.
8. Gavioli M, Luppi G, Losi L, et al: Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 2005; 48: 1851-1857.
9. Capirci C, Velantini V, Cionini L, et al: Prognostic value of complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107.
10. Vecchio FM, Valentini V, Minsky B, et al: The relationship of pathological tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62: 752-760.
11. Theodoropoulos G, Wise WE, Padmanabhan A, et al: T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: 895-903.
12. Kuo LJ, Liu MC, Jian JJM, et al: Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 2007; 14: 2766-2772.
13. Losi L, Luppi G, Gavioli M, et al: Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 2006; 21: 645-651.
14. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4):S9-S15.
15. Galizia G, Lieto E, Ferraraccio F, et al: Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13: 823-835.
16. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs tumor response to radiation. Cancer Cell 2004; 6: 553-563.
17. Kim MY, Zhang T, Kraus WL: Poly(ADP-ribosyl) ation by PARP-1: 'PAR-laying' NAD + into a nuclear signal. Genes Dev 2005; 19: 1951-1967.
18. Schreiber V, Dantzer F, Amè JC, et al: Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528.
19. Brem R, Hall J: XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 2005; 33: 2512-2520.
20. Laurent A, Nicco C, Chereau C, et al: Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-956.
21. Lu AL, Li X, Gu Y, et al: Repair of oxidative DNA damage: mechanisms and functions. Cell Biochem Biophys 2001; 35: 141-170.
22. Audebert M, Salles B, Calsou P: Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004; 279: 55117-55126.
23. Aschele C, Lonardi S, Monfardini S: Thymidylate synthase expression as predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002; 28: 27-47.
24. Rödel C, Grabenbauer GC, Rödel F, et al: Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46: 1213-1221.
25. Carlomagno C, Farella A, Bucci L, et al: Neoadjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009; 20: 906-912.
26. Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994; 73: 2680-2686.
27. Hanley JA, McNeil BJ: The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
28. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
29. Breslow NE, Day NE: Statistical methods in cancer research. Vol.I - The analysis of casecontrol studies. IARC Sci Publ 1980; 32: 5-338.
30. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
31. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972; 135: 185-206.
32. Giralt J, Eraso A, Armengol M, et al: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1460-1465.
33. Motlagh A, Azadeh P, Fazlalizadeh A, et al: Expression of epidermal growth factor receptor as a predictive factor for rectal cancer. Arch Iran Med 2007; 10: 301-308.
34. Kim JS, Kim JM, Li S, et al: Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 195-200.
35. Zlobec I, Vuong T, Hayashi S, et al: A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007; 96: 793-800.
36. Zlobec I, Vuong T, Compton CC, et al: Combined analysis of VEGF and EGFR predicts complete tumor response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008; 98: 450-456.
37. Bertolini F, Bengala C, Losi L, et al: Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1455-1461.
38. Edler D, Glimelius B, Hallstrom M, et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracilbased chemotherapy. J Clin Oncol 2002; 20: 1721-1728.
39. Jakob C, Aust DE, Meyer W, et al: Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004; 204: 562-568.
40. Jakob C, Liersch T, Meyer W, et al: Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil- based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 2005; 29: 1304-1309.
41. Negri FV, Campanini N, Camisa R, et al: Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008; 98: 143-147.
42. Yeh KH, Cheng AL, Wan JP, et al: Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 2004; 15: 371-376.
43. Lindebjerg J, Nederby J, Hoeffding LD, et al: Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. APMIS 2005; 113: 600-602.
44. Edler D, Hallstrom M, Ragnhammar P, et al: Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression. Anticancer Res 2002; 22: 3113-3116.
45. Jacob C, Liersch T, Meyer W, et al: Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 2008; 14: 1060-1066.
46. Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
47. Wachsberger P, Burd R, Dicker AP: Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 2004; 18: 1039-1057.
48. Zlobec I, Steele R, Compton CC: VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005; 104: 2517-2521.
49. Hu J, Smith TR, Miller MS, et al: Amino acid substitution variants of APE1 and XRCC1 genes associated with IR sensitivity. Carcinogenesis 2001; 22: 917-922.
50. Taverna P, Hwang HS, Schupp JE, et al: Inhibition of base excision repair potentiates iododeoxyuridine- induced cytotoxicity and radiosensitization, Cancer Res 2003; 63: 838-846.
51. Stoehlmacher J, Ghaderi V, Iobal S, et al: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21: 3075-3079.
52. Suh KW, Kim JH, Kim DY, et al: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006; 13: 1379-1385.
53. Cimmino G, Pepe S, Laus G, et al: Poly(ADPR) polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54 p53wt and U251 p53mut glioblastoma cell lines. Pharmacol Res 2007; 55: 49-56.
54. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al: Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2: 371-382.
55. Donawho CK, Luo Y, Luo Y, et al: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNAdamaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737.
56. Calabrese CR, Almassy R, Barton S, et al: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.